Skip to main content
. 2016 Aug 24;7(41):67129–67141. doi: 10.18632/oncotarget.11562

Figure 6. H2-18 potently inhibits the growth of trastuzumab-resistant tumors in vivo.

Figure 6

Tumor volume of HCC-1954 breast tumor xenografts after treatment with control IgG (10 mg/kg, twice a week, intravenously), trastuzumab (10 mg/kg, twice a week, intravenously), pertuzumab (10 mg/kg, twice a week, intravenously), trastuzumab plus pertuzumab (10 mg/kg for each, twice a week, intravenously) and H2-18 (10 mg/kg, twice a week, intravenously). Data are shown as means ± SEM. *, P<0.05; **, P<0.01; Mann-Whitney test.